These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37821875)

  • 1. Efficacy and safety of blonanserin versus risperidone in the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
    Deng SW; Xu Q; Jiang WL; Hong B; Li BH; Sun DW; Yang HB
    BMC Psychiatry; 2023 Oct; 23(1):740. PubMed ID: 37821875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: A double-blind, parallel-group multicenter randomized trial.
    Li H; Yao C; Shi J; Yang F; Qi S; Wang L; Zhang H; Li J; Wang C; Wang C; Liu C; Li L; Wang Q; Li K; Luo X; Gu N
    J Psychiatr Res; 2015 Oct; 69():102-9. PubMed ID: 26343601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blonanserin vs risperidone in Japanese patients with schizophrenia: A post hoc analysis of a phase 3, 8-week, multicenter, double-blind, randomized controlled study.
    Harvey PD; Nakamura H; Miura S
    Neuropsychopharmacol Rep; 2020 Mar; 40(1):63-72. PubMed ID: 31788985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of antipsychotic treatments for schizophrenia: A systematic review and network meta-analysis of randomized trials in Japan.
    Kishi T; Ikuta T; Sakuma K; Okuya M; Iwata N
    J Psychiatr Res; 2021 Jun; 138():444-452. PubMed ID: 33964682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials.
    Kishi T; Matsuda Y; Nakamura H; Iwata N
    J Psychiatr Res; 2013 Feb; 47(2):149-54. PubMed ID: 23131856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Model-based analysis of therapeutic efficacy of blonanserin and risperidone in schizophrenia patients and effects on prolactin: A randomized double-blind study.
    Yu W; Lei L; Yu Y; Li Y; Shen Y; Li H
    Hum Psychopharmacol; 2020 Jan; 35(1):e2717. PubMed ID: 31837240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, Tolerability, and Safety of Blonanserin in Schizophrenia: An Updated and Extended Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Kishi T; Matsui Y; Matsuda Y; Katsuki A; Hori H; Yanagimoto H; Sanada K; Morita K; Yoshimura R; Shoji Y; Hagi K; Iwata N
    Pharmacopsychiatry; 2019 Feb; 52(2):52-62. PubMed ID: 29514360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial.
    Li H; Luo J; Wang C; Xie S; Xu X; Wang X; Yu W; Gu N; Kane JM
    Schizophr Res; 2014 Aug; 157(1-3):112-9. PubMed ID: 24994555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wendan decoction (Traditional Chinese medicine) for schizophrenia.
    Deng H; Xu J
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD012217. PubMed ID: 28657646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quetiapine versus other atypical antipsychotics for schizophrenia.
    Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
    Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study.
    Garcia E; Robert M; Peris F; Nakamura H; Sato N; Terazawa Y
    CNS Drugs; 2009; 23(7):615-25. PubMed ID: 19552488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
    Kishi T; Matsuda Y; Iwata N
    PLoS One; 2014; 9(2):e88049. PubMed ID: 24505373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blonanserin: a review of its use in the management of schizophrenia.
    Deeks ED; Keating GM
    CNS Drugs; 2010 Jan; 24(1):65-84. PubMed ID: 20030420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risperidone versus placebo for schizophrenia.
    Rattehalli RD; Zhao S; Li BG; Jayaram MB; Xia J; Sampson S
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD006918. PubMed ID: 27977041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paliperidone palmitate for schizophrenia.
    Nussbaum AM; Stroup TS
    Cochrane Database Syst Rev; 2012 Jun; (6):CD008296. PubMed ID: 22696377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial.
    Chan HY; Lin WW; Lin SK; Hwang TJ; Su TP; Chiang SC; Hwu HG
    J Clin Psychiatry; 2007 Jan; 68(1):29-36. PubMed ID: 17284127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute Antipsychotic Treatment of Children and Adolescents With Schizophrenia-Spectrum Disorders: A Systematic Review and Network Meta-Analysis.
    Pagsberg AK; Tarp S; Glintborg D; Stenstrøm AD; Fink-Jensen A; Correll CU; Christensen R
    J Am Acad Child Adolesc Psychiatry; 2017 Mar; 56(3):191-202. PubMed ID: 28219485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of perospirone in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
    Kishi T; Iwata N
    CNS Drugs; 2013 Sep; 27(9):731-41. PubMed ID: 23812802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
    Loy JH; Merry SN; Hetrick SE; Stasiak K
    Cochrane Database Syst Rev; 2012 Sep; (9):CD008559. PubMed ID: 22972123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.